Axon Therapies, Inc.

Axon Therapies, Inc. (registered trade name of Axon Vascular, Inc.) is a clinical-stage medtech company developing the Satera Ablation System for treatment of heart failure with preserved ejection fraction (HFpEF). The company's proprietary SAVM (Splanchnic Ablation for Volume Management) procedure uses an ablation catheter to target the greater splanchnic nerve via percutaneous venous access, aiming to reduce sympathetic nervous system activity and normalize volume balance in heart failure patients. The minimally invasive, implant-free outpatient procedure typically takes under one hour. Axon's lead investigational device is the Axon Ablation Catheter, designed to deliver targeted ablation therapy to block sympathetic nerve signals and reverse cardiac congestion. The company is currently conducting the Rebalance-HF clinical trial (NCT04592445), which demonstrated 12-month results showing reduced pulmonary capillary wedge pressure (PCWP) by 18 mmHg versus sham, improved quality of life (KCCQ +17), and increased six-minute walk distance (+49 meters). The device is investigational and not yet approved for clinical use in any geography. Axon is backed by institutional investors including Deerfield Management, Action Potential Venture Capital (GSK's bioelectronic medicines fund), and has assembled an experienced leadership team with deep medtech commercialization expertise and clinical advisory board comprising leading cardiologists from Mayo Clinic, Duke University, Northwestern University, Mount Sinai, and the Medical University of South Carolina. The company maintains offices in New York and Altrincham, United Kingdom.